Skip to main content

Zyomyx to Develop Biochips Using Dyax s Phage Display Technology

NEW YORK, March 27 - In an effort to develop its protein biochips, Zyomyx said Tuesday it has licensed phage display antibody technology from Dyax.

The agreement is the second antibody collaboration for Zyomyx, which first teamed up with Cambridge Antibody Technology (CAT) last December for access to antibodies in CAT's phage display libraries. 

In the arrangement with Dyax, Zyomyx will receive a non-exclusive license to Dyax's phage display technology for developing antibodies to specific proteins for use in a protein biochip. The companies did not disclose financial terms of the deal, but said that the agreement involves both fees for R&D and royalties on future product sales.

Last week, diagnostics manufacturer Biosite said it had developed a prototype protein microarray with 100 antibodies. While Zyomyx has yet to announce the development of a large-scale prototype, Zyomyx CEO Lawrence Cohen said recently that the company plans to release beta versions of chips that will have densities of up to 10,000 proteins per square centimeter later this year.

Zyomyx, of Hayward, Calif., also has partnerships with Fujirebo, a Japanese developer of diagnostics tools, and MDS Proteomics of Toronto.

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.